Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | ||||||
{[ item.p_purity ]} | {[ item.pr_size ]} | Inquiry |
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price) ]} |
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price) ]} | Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate,item.pr_is_large_size_no_price) ]} | {[ item.pr_usastock ]} | in stock Inquiry - | {[ item.pr_chinastock ]} | {[ item.pr_remark ]} in stock Inquiry - | Login | Inquiry |
Please Login or Create an Account to: See VIP prices and availability
Johansson Joel ; Link?ping University,2024.
More
Abstract: As of today, Alzheimer’s disease is the leading cause of dementia among neurodegenerative disorders, affecting many millions of people worldwide. As the average life span of populations increase, more and more people succumb to the illness each year. Like other neurodegenerative disorders, Alzheimer’s disease can be attributed to the accumulation of protein aggregates in the brain. These amyloid-β peptides and tau proteins can presumably be detected in the brain many years before the onset of clinical symptoms. Development of fluorescent ligands, capable of binding to these neuropathological hallmarks and highlighting them, could serve as molecular diagnostic tools and facilitate an early diagnosis of the disease. The method could also be useful in studying disease progression and evaluating the effects of novel treatments. One such ligand is HS-259. The aim of this project was to synthetize different analogues of HS-259, and test their selectivity towards the aforementioned aggregates in brain tissue from an individual with Alzheimer’s disease. Staining of tissue samples with analogue solution enables visualization of aggregate sites through fluorescence imaging. In the end, five analogues were synthetized, albeit in relatively low overall yields. Synthetic methods included Suzuki-Miyara cross-couplings, Ullmann-type arylations and condensations. Liquid Chromatography-Mass Spectrometry (LC-MS) and Nuclear Magnetic Resonance (NMR) were used for analysis of the compounds. Two of the five analogues could be tested for staining of aggregates and assessed for photophysical characteristics, i.e. absorption- and emission spectra. One analogue stained both amyloid-β aggregates and some tau aggregates, whereas the other stained neither. Since only two analogues were tested and rendered inconsistent results, further studies are needed to assess the binding properties of HS-259 analogues in general.
Keywords: Alzheimer's disease ; neurodegenerative disorders ; protein aggregates ; molecular ligands ; amyloid-β ; Aβ ; amyloid-beta ; tau ; diagnosis ; HS-259 ; staining ; brain tissue ; Suzuki coupling ; Ullmann arylation ; condensation ; NMR ; nuclear magnetic resonance ; LC-MS ; liquid chromatography ; neuropathological hallmarks ; absorption spectra ; emission spectra ; synthesis ; plaques ; symptoms ; neuropathology ; thiophene-vinyl-benzothiazole ; TVBT ; ligand analogues ; N-arylation ; Knoevenagel ; preparative LC ; PBS ; phosphate buffered saline ; treatments ; AD ; mechanisms ; thiophene ; benzothiazolium ; fluorescence imaging ; bTVBT ; bi-thiophene-vinyl-benzothiazole ; detection ; Suzuki-Miyara ...More
Purchased from AmBeed: 3176-62-3
CAS No. : | 3176-62-3 | MDL No. : | MFCD00601361 |
Formula : | C8H8N2 | Boiling Point : | - |
Linear Structure Formula : | C7H5(CH3)N2 | InChI Key : | FWOPJXVQGMZKEP-UHFFFAOYSA-N |
M.W : | 132.16 | Pubchem ID : | 820804 |
Synonyms : |
|
Signal Word: | Warning | Class: | N/A |
Precautionary Statements: | P261-P280-P305+P351+P338 | UN#: | N/A |
Hazard Statements: | H302-H315-H317-H319-H335 | Packing Group: | N/A |
GHS Pictogram: |
[ 5757-85-7 ]
1,3-Dimethyl-1H-indazol-5-amine
Similarity: 0.86